Patents by Inventor Attila VIRAG

Attila VIRAG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250042865
    Abstract: ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(?)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.
    Type: Application
    Filed: March 4, 2024
    Publication date: February 6, 2025
    Applicant: EGIS GYÓGYSZERGYÁR ZRT.
    Inventors: Zsuzsanna SZOKOL, Tamás NAGY, András Balázs DANCSÓ, Attila VIRÁG, Regina NÉMETHNÉ CSILLAG, Károly LOZSI, Balázs VOLK, László SZLÁVIK
  • Patent number: 12018005
    Abstract: ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(?)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.
    Type: Grant
    Filed: July 25, 2023
    Date of Patent: June 25, 2024
    Assignee: EGIS GYÓGYSZERGYÁR ZRT.
    Inventors: Zsuzsanna Szokol, Tamás Nagy, András Balázs Dancsó, Attila Virág, Regina Némethné Csillag, Károly Lozsi, Balázs Volk, László Szlávik
  • Patent number: 10023566
    Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: July 17, 2018
    Assignee: EGIS GYOGYSZERGYAR ZRT
    Inventors: Ede Laszlo Marvanyos, Attila Virag, Tamas Gregor, Balazs Volk, Maria Tothne Lauritz, Laszlo Pongo, Balazs Peregi, Gyula Lukacs, Zoltan Varga, Andras Dancso
  • Publication number: 20170183334
    Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.
    Type: Application
    Filed: May 26, 2015
    Publication date: June 29, 2017
    Applicant: EGIS GYOGYSZERGYAR ZRT
    Inventors: Ede Laszlo MARVANYOS, Attila VIRAG, Tamas GREGOR, Balazs VOLK, Maria TOTHNE LAURITZ, Laszlo PONGO, Balazs PEREGI, Gyula LUKACS, Zoltan VARGA, Andras DANCSO